Malignant mesothelioma, primarily located in the pleura, is a locally aggressive tumor. Distant metastases are rarely seen and mostly diagnosed postmortem. We present the third malignant pleural mesothelioma (MPM) case in the literature with bone marrow metastasis. A 36-year-old male patient presented with pain at the right mediastinal area and 5 Â 6cm mass on the right side of his chest. 18-FDG positron emission tomography (PET) scan showed local uptake at the pleura, regional lymph nodes and 5th rib. The tru-cut biopsy reported as sarcomatoid type MPM. Cisplatin-pemetrexed therapy was planned. His medical condition deteriorated after 2 months and multiple metastases to brain, liver, adrenal glands and bone marrow were detected. The patient was lost 4 months after he was diagnosed. Brain and bone marrow metastasis of MPM are rarely seen. Physicians should be careful about the rapid progression and unexpected metastases of MPM.
Introduction
Malignant pleural mesothelioma (MPM), mostly associated with asbestos, is a malignancy arising from mesothelial or subserosal cells of the pleura, peritoneum and pericardium. The symptoms are usually late-onset and nonspecific. The median survival period is 9e12 months. 1 MPM is highly resistant to chemotherapy and a limited number of patients are suitable for surgery. At the time of the diagnosis, 10e50% of the patients have disseminated disease. 2 The major sites for metastases are lung, regional lymph nodes, liver (especially in sarcomatoid pattern), adrenal glands and kidney. 3 The rarely seen extrathoracic sites for tumor dissemination are spleen, thyroid and brain. 4 Herein, we presented a case of MPM with distant metastases to brain, liver, adrenal glands and bone marrow. To our knowledge, this is the third MPM case in the literature with bone marrow metastases.
Case report
A 36-year-old male patient referred to our oncology clinic in /L. Bone marrow aspiration was performed. 15 days later, January 2016, he referred to our emergency service with abdominal pain. The abdominal ultrasonography revealed hypoechoic nodular liver lesions (2.5cm in diameter) and 5 Â 3cm nodules on left surrenal gland, both were interpreted as metastatic lesions. Because patient's ECOG PS decreased to 3, his pain increased and respiratory failure developed, he was again admitted to the hospital. Liver biopsy was performed. Three days after his admission, he complained about ptosis, diplopia and limitations in view. An ophthalmologic examination and cranial MRI was performed. It showed metastatic mass at the superior orbital fissure invading clivus, which clarified ophthalmologic complaints, and dural metastasis at cervical spine. Intrathecal dexamethasone and methotrexate injection was done for dural metastasis. Bone marrow and liver biopsy results were compatible with mesothelioma. We planned 2nd line chemotherapy; gemcitabine, 1000mg/m 2 . Patient received the first course of treatment but his respiratory failure worsened. He died following the deterioration of his medical condition in February 2016.
Discussion
MPM is a rare tumor with poor prognosis. Most of the cases are pleura originated and locally aggressive, metastazing to an organ in close proximity along the serosa membrane. 4 Regional lymph nodes are the major metastatic sites seen in 40% of the cases. 5 The prognosis depends on the patient's age, gender, tumor stage and histological type of the mesothelioma. 6 Although young age has better survival rates, in a study done by Yamagishi et al. on brain metastases in malignant pleural mesothelioma, multivariate analysis showed that <65 years of age is independently associated with brain metastasis, also seen in our 36-year-old patient.
7
Another important factor associated with poor prognosis in MPM is histological subtype of the disease. Epitheloid subtype is shown to have a better overall survival. 8 Although Yamagishi et al.
found no histological difference among brain metastatic patients, Miller et al. showed that the sarcomatoid subtype predominates among these patients. 7, 9 Our patient also had sarcomatoid type MPM which might explain the rapid dissemination of the tumor to multiple distant sites -liver, adrenal glands, brain and bone marrow-within 4 months. 11, 12 Skeletal muscle metastasis and subcutaneous nodules are also described in few MPM cases. 13, 14 Knipscheer et al. reported two MPM cases with bone marrow metastasis diagnosed with bone marrow biopsy done after an FDG uptake seen in PET scan. 15 Herein, we reported the third MPM case with bone marrow metastasis known in the literature. Since PET scan was just done a month ago and showed no distant metastases, the diagnosis of bone marrow metastasis could easily be overlooked. Leukocytosis was also another remarkable entity. Since pancytopenia was expected during chemotherapy, leukocytosis development deserved the differential diagnosis. Consequently, physicians should always be on the alert for the rapid progression and unexpected metastases of MPM.
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